Hopp til innhold
Close

Get alerts of updates about «SeroSelectTB»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • SeroSelectTB

Oops, something went wrong...

... contact nettredaksjon@fhi.no.

... reload the page and try again-

Project

SeroSelectTB - project description

Published Updated

SeroSelectTB is a multinational project coordinated by the Norwegian Institute of Public Health.

SeroSelectTB logo with financing logos.png

Summary

The performance of a new triage test for active tuberculosis, SeroSelectTB, will be qualified in multi-centre randomised controlled trials at health-posts in South Africa, Tanzania and Ethiopia. Cost effectiveness evaluations will be conducted to support a value proposition to stakeholders and regulatory authorities, and to support commercialization requirements. Consenting adults will provide blood and saliva samples for screening by SeroSelectTB, and sputum collected for routine TB diagnosis by the health services. Clinical and sociodemographic information will be collected. A reliable rapid test will make it possible to identify and selectively treat those with active TB at the local healthcare level. The expected impact includes accurate same-day diagnosis of patients with active TB, reduction of diagnostic delay and TB transmission, and diagnostic cost-savings for patients and healthcare systems in high burden countries.

SeroSelectTB is a multinational project coordinated by the Norwegian Institute of Public Health (Oslo, Norway). Partners include Stellenbosch University and Lateral Flow Laboratories (South Africa), Kilimanjaro Christian Medical University College (Tanzania), Armauer Hansen Research Institute (Ethiopia), National Institute for Public Health and the Environment (Netherlands), InVivo Biotech Services GmbH (Germany), Aether Dynamics Consulting & Trading GmbH (Austria), and E-MEDDIA (France).

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Carol J C Holm-Hansen, Smittevern, miljø og helse, Norwegian Institute of Public Health

Project participants

Tara Kelly Dolgner, Avdeling for forskningsadministrativ støtte, Norwegian Institute of Public Health
Ida Laake, Smittevern, miljø og helse, Norwegian Institute of Public Health
Grant Theron, University of Stellenbosch
Anna Ojo, University of Stellenbosch
Balthazar Nyombi, Kilimanjaro Christian Medical University College
Kidist Bobosha, AHRI Armauer Hansen Research Institute
Kristin Kremer, National Institute for Public Health and the Environment
Nick Borain, Lateral Flow Laboratories (Pty) Ltd
Tim Welsink, InVivo Biotech Services GmbH
Aleksandar Josifoski, Aether Dynamics Consulting and Trading GmbH
Fatima Gruszka, E-MEDDIA
Miloje Savic, E-MEDDIA

Start

01.01.2020

End

31.12.2023

Status

Active

Financing

European and Developing Countries Clinical Trials Partnership (EDCTP) grant code: RIA2018D-2493

Approvals

Regional committees for medical and health research ethics

Project owner/ Project manager

Norwegian Institute of Public Health

Participant at FHI

Ida Laake

Tara Kelly Dolgner

External participants

ADDITIONAL PARTICIPANTS: Byron Reeve – Stellenbosch University •Shima Abdulgader – Stellenbosch University •Julianne du Plessis - Lateral Flow Laboratories •Saumu Pazia Juma - Kilimanjaro Clinical Research Institute •Tamirat Assefa - Armauer Hansen Research Institute •Solomon Yimer - Armauer Hansen Research Institute